efficacy of atorvastatin plus aspirin in comparison with atorvastatin alone on liver function and degree of fibrosis in patients with cryptogenic cirrhosis: a randomized double-blind clinical trial

Objectives: this study was conducted to evaluate the efficacy of a combination therapy using aspirin (also known as acetylsalicylic acid (asa)) and atorvastatin in comparison with atorvastatin alone to improve liver fibrosis and function in patients with cryptogenic cirrhosis. methods: in this randomized double-blinded clinical trail, 40 patients with cryptogenic cirrhosis were randomly allocated to the intervention group (atorvastatin + asa) and the control group (atorvastatin) treated for six months. then liver function and stiffness (based on transient electrography) were compared. a checklist was used for data collection and the results were analyzed by spss 24 using chi-square test and paired t-test at the 0.05 significance level. results: a total of 33 cases, including16 patients in group a (atorvastatin + asa) and 17 in group b (atorvastatin + placebo) with a mean age of 50.3 ± 11.2 and 47.9 ± 10.6 years and bmi of 30.7 ± 4.2 and 30.8± 3.1 in groups a and b, were studied, respectively. twelve patients (75%) in group a and 14 cases (82%) in group b were male. both groups were homogenized in terms of demographic information at baseline. a significant improvement in child score (p = 0.001 and p = 0.002 for groups a and b, respectively) and liver stiffness (p < 0.0001 and p = 0.007 for groups a and b, respectively) were observed in both groups after the intervention, however there was no significant improvement in child score (p = 0.982) and liver stiffness (p = 0.611) in comparing both groups. conclusions: although atorvastatin is effective in improvement of liver fibrosis and function in cryptogenic cirrhosis, adding asa cannot improve its effects.